Stockwinners Market Radar for October 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 103K shares of Tempus AI today

19:50 EDT AGBA Group Holding Ltd trading halted, news pending

19:50 EDT Sharps Technology Inc trading halted, news pending

19:09 EDT Crowdstrike director sells $2.0M in common stock - In a regulatory filing, Crowdstrike disclosed that its director Sameer Gandhi sold 6,250 shares of common stock on October 11th in a total transaction size of $2.0M.

18:50 EDT L3Harris Technologies appoints David Regnery to Board of Directors - L3Harris Technologies announced that David S. Regnery, Chair and CEO of Trane Technologies has been appointed to its Board of Directors. Regnery was appointed CEO of Trane Technologies in July 2021, and named Chair of its Board of Directors in January 2022. Previously, Mr. Regnery served as Trane Technologies' President and Chief Operating Officer, with direct responsibility for its three regional reportable segments and entire portfolio of businesses, as well as mission-critical company operations, including supply chain, engineering and information technology. Regnery is the third independent director that L3Harris and the D.E. Shaw group agreed to be added to the Company's Board, pursuant to their December 2023 cooperation agreement.

18:47 EDT L3Harris Technologies appoints David Regnery as CEO - L3Harris Technologies announced that David S. Regnery, Chair and CEO of Trane Technologies has been appointed to its Board of Directors. Regnery was appointed CEO of Trane Technologies in July 2021, and named Chair of its Board of Directors in January 2022. Previously, Mr. Regnery served as Trane Technologies' President and Chief Operating Officer, with direct responsibility for its three regional reportable segments and entire portfolio of businesses, as well as mission-critical company operations, including supply chain, engineering and information technology. Regnery is the third independent director that L3Harris and the D.E. Shaw group agreed to be added to the Company's Board, pursuant to their December 2023 cooperation agreement.

17:54 EDT Sonos unveils new premium soundbar Arc Ultra - Sonos announced the introduction of Sonos Arc Ultra, a new premium soundbar that also debuts the brand's transducer technology called Sound Motion. Sound Motion drastically reduces the size of the transducer while supercharging the bass. Arc Ultra delivers up to double the bass of its predecessor, with an unprecedented 9.1.4 spatial audio experience in a sleek, sophisticated design, the company said. Sonos is also introducing Sonos Sub 4, the next generation of our iconic subwoofer with a refreshed design and internals that elevate your favorite movies, hit shows and more with rumbling bass. "For decades, Sonos has revolutionized home theater and music experiences with products that look as great as they sound. Driven by our hunger for innovation, we created Sound Motion(TM) to break the boundaries of what's possible by a single speaker, bringing this industry-first transducer technology to home theater where demand for extraordinary sound is equal to designs that fit modern living spaces," said Patrick Spence, CEO of Sonos. "Arc Ultra is a reimagination of our best-selling soundbar, leveraging this incredible innovation to deliver an unprecedented sound experience from a sleeker design." Arc Ultra and Sub 4 will be available beginning on October 29, 2024 for $999 and $799. Reference Link

17:46 EDT Costco exec sells $3.9M in common stock - In a regulatory filing, Costco disclosed that its Sr. EVP Russell Miller sold 4.4K shares of common stock on October 11th in a total transaction size of $3.9M.

17:27 EDT Container Store receives $40M investment from Beyond - Container Store (TCS) and Beyond (BYON) announced that the companies have entered into a strategic partnership with the objective to improve customer experience. The companies intend for the partnership to position Container Store to return to profitable comparable store growth over time by utilizing Beyond's intellectual property, customer data, network of brands, and affiliate relationships. The companies expect key aspects of the partnership to include: Container Store's real estate locations and utilizing the Bed Bath & Beyond brand to launch appropriately sized spaces that showcase the Bed Bath & Beyond assortment for kitchen, bath and bedroom, which will be co-branded. Through this collaboration, the companies expect to drive increased traffic for Container Store's core assortment and its high-margin, solution-driven Custom Spaces services business. Beyond will offer a global loyalty program, multiple payment solutions and ancillary insurance and protection products through Container Store brick-and-mortar locations and website in an effort to capitalize on the whitespace opportunity for Custom Spaces and increase conversion of design leads to drive growth through the vertically integrated model. Beyond to integrate Container Store's proprietary Custom Spaces offering, including its Elfa and Preston product lines, across Beyond's portfolio of e-commerce banners as well as other ventures where Bed Bath & Beyond future licensed stores exist globally. Container Store will join Beyond's data platform and Beyond to assist with expanded and renewed e-commerce platforms and strategies. As part of the terms of the collaboration, Beyond has agreed to invest $40M in The Container Store through a preferred equity transaction subject to certain terms and conditions, including an amendment or refinancing of The Container Store's credit facilities in a manner commercially acceptable to Beyond.

17:02 EDT New York Community Bancorp changes name to Flagstar Financial, ticker to FLG - New York Community Bancorp announced that its Board of Directors approved and adopted an amendment to the company's Amended and Restated Certificate of Incorporation, changing the company's name to Flagstar Financial. As a result of the Name Change, which will become effective on October 25, 2024, at 5:00 pm ET, the company expects that its common stock, which trades on the New York Stock Exchange, will cease trading under the ticker symbol "NYCB" and commence trading on the NYSE under the ticker symbol "FLG" effective as of the open of business on October 28, 2024. In addition, effective as of that same time, the company expects that the NYSE ticker symbol for the company's Bifurcated Option Note Unit SecuritiESSM will change to "FLG PRU" from "NYCB-PU" and the ticker symbol for the Company's Depositary Shares, each representing a 1/40th interest in a share of Series A Noncumulative Perpetual Preferred Stock, will change to "FLG PRA" from "NYCB-PA". No action is required by shareholders and the applicable CUSIPs will remain unchanged.

16:45 EDT FDA approves Novocure's Optune Lua in mNSCLC - Novocure "announced that the FDA has approved Optune Lua(R) for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer, or mNSCLC, who have progressed on or after a platinum-based regimen. Optune Lua is a portable device that produces alternating electric fields known as tumor treating fields - TTFields- which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death. The Phase 3 LUNAR study was a prospective, randomized, open-label, multicenter study that compared the use of Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel to PD-1/PD-L1 inhibitors or docetaxel alone for patients with metastatic NSCLC who progressed during or after platinum-based therapy. The primary endpoint of the study was achieved demonstrating a statistically significant and clinically meaningful 3.3-month extension in median overall survival for patients treated with Optune Lua concurrently with a PD-1/PD-L1 inhibitor or docetaxel. The group treated with Optune Lua concurrently with a PD-1/PD-L1 inhibitor or docetaxel had a median OS of 13.2 months compared to a median OS of 9.9 months in the PD-1/PD-L1 inhibitor or docetaxel treated group."

16:37 EDT Copa Holdings: September ASMs up 9.1%, RPMs increased by 7.3%, compared to 2023 - For September 2024, Copa Holdings' capacity ASMs increased by 9.1%, while system-wide passenger traffic RPMs increased by 7.3%, compared to 2023. As a result, the system load factor for the month was 85.9%, 1.4 percentage points lower than in September 2023.

16:34 EDT UroGen Pharma announces FDA acceptance of new drug application for UGN-102 - UroGen Pharma "announced FDA acceptance of the New Drug Application for investigational drug UGN-102 for intravesical solution. UGN-102 could become the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has assigned a Prescription Drug User Fee Act goal date of June 13, 2025." Mark Schoenberg, Chief Medical Officer of UroGen, stated, "The NDA for UGN-102 is backed by a robust data set demonstrating impressive durability of response across three clinical trials and a favorable safety profile. Notably, the ENVISION trial successfully met its primary endpoint, showing a 79.6% complete response rate at three months after the first instillation of UGN-102. Additionally, the latest results from that trial revealed an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who achieved a complete response at 3 months. The most common treatment-emergent adverse events in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention. Additionally, the safety profile observed in the ENVISION trial was consistent with that seen in other studies of UGN-102. We believe that, if approved, UGN-102's ability to achieve durable complete responses and potentially reduce recurrence rates while extending treatment-free intervals will represent a significant advance in managing LG-IR-NMIBC."

16:30 EDT Liberty Energy raises quarterly dividend 14% to 8c per share - Liberty Energy announced that its Board of Directors has declared a dividend of 8c per share of Class A common stock, to be paid on December 20, 2024, to holders of record as of December 6, 2024. This dividend represents a 14% increase from the prior regular quarterly dividend of 7c per share. "Liberty's disciplined investment in innovative businesses and leading edge technologies expands our competitive advantage and increases our market opportunities in the coming years. We are increasing our quarterly cash dividend by 14%, consistent with our long-term objective of generating strong total shareholder value including a balanced return of capital program," commented Chris Wright, Chief Executive Officer.

16:20 EDT Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - Biodexa Pharmaceuticals announced that a Nasdaq Hearings Panel has granted the company's request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq Stock Market set forth in Nasdaq Listing Rule 5550. As a condition of the panel's decision, the company is required to demonstrate compliance with the minimum bid price requirement by evidencing a closing bid price of at least $1.00 per share for a minimum of 20 consecutive trading days by October 31.

16:19 EDT Kintara Therapeutics corrects previous press release - Kintara Therapeutics announced a correction to the press release previously issued by Kintara on October 14, regarding a record date for the issuance of the Contingent Value Rights to stockholders of Kintara pursuant to the definitive merger agreement with TuHURA Biosciences. Kintara announced that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, but rather will be issued stockholders of record of Kintara immediately prior to the planned reverse stock split that will be consummated immediately prior to the proposed Merger. Accordingly, the announcement of a record date for the CVRs made by Kintara on October 14 is hereby retracted. Kintara does not anticipate that this correction and retraction will affect the stockholders of record who will receive the CVRs or the number of CVRs to be received by them. As previously announced, Kintara's stockholders approved a reverse stock split of Kintara's common stock in a range of 1-for-20 to 1-for-40 at Kintara's special meeting of stockholders held on October 4, 2024. Kintara expects to effect a reverse stock split at a ratio of 1-for-35 immediately prior to the consummation of the proposed Merger. The proposed Merger is expected to close on October 18 subject to regulatory approval and the satisfaction of the remaining closing conditions under the Merger Agreement. In connection with the proposed Merger and pursuant to the Contingent Value Rights Agreement (the "CVR Agreement") to be entered into prior to the Closing Date, Kintara will issue a number of CVRs to Kintara stockholders entitling the holders thereof to an aggregate of 53,897,125 shares of Kintara's common stock, which number is subject to adjustment as a result of Kintara's proposed reverse stock split described above upon the achievement of certain milestones as set forth in the CVR Agreement. Kintara stockholders of record immediately prior to the reverse stock split will receive one CVR per share of Kintara common stock (or in the case of warrants to purchase shares of Kintara common stock, each share of Kintara common stock for which such warrant to purchase shares of Kintara stock is exercisable) each respectively owned. The CVRs will be issued immediately prior to the proposed reverse stock split and closing of the proposed Merger. Equiniti Trust Company, LLC is acting as the rights agent for CVRs. Stockholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the issuance of CVRs. Beneficial holders are encouraged to contact their bank, broker or custodian with any procedural questions.

16:13 EDT Tencent's Riot to lay off 32 workers - Tencent's Riot Games, the game maker behind "League of Legends" and "Valorant," announced via X, formerly Twitter, that it will eliminate certain roles. "This isn't about reducing headcount to save money-it's about making sure we have the right expertise so that League continues to be great for another 15 years and beyond," said Riot's Marc Merill. "While team effectiveness is more important than team size, the League team will eventually be even larger than it is today as we develop the next phase of League. For Rioters who are laid off, we're supporting them with a severance package that includes a minimum of six months' pay, annual bonus, job placement assistance, health coverage, and more." A spokesperson told The Verge that 32 staffers will be laid off. Reference Link

16:09 EDT Agba completes merger with Triller, jurisdiction changed to Delaware - AGBA Group Holding Limited announced the completion of its previously announced merger with Triller. In connection with the Merger, AGBA has changed its name to Triller Group. The combined company's common stock and warrants are expected to begin trading under the tickers "ILLR" and "ILLRW," respectively, on Nasdaq Capital Market on October 16...The Company will make a statement on future leadership, strategy and objectives on Tuesday, October 22. Domestication to Delaware...Concurrent with the closing of the Merger, AGBA changed its jurisdiction of incorporation from the British Virgin Islands to the State of Delaware, and changed its corporate name to "Triller Group". Following the completion of the Merger, former AGBA shareholders and former Triller stockholders own 30% and 70% of the combined company's outstanding common stock, respectively.

16:08 EDT Actelis Networks receives new follow-on order from aerial transportation agency - Actelis Networks announced that it has received a new follow-on order in new geographies from an aerial transportation agency operating underneath the umbrella of the U.S. Department of Transportation. This follows the order previously announced by Actelis in September, for the same agency. The project calls for advanced technology to support the backhaul of radar communications-critical for ensuring air safety and smooth operations. Actelis' solution enables reliable transmission of radar data to air traffic control centers, providing the high bandwidth and security essential in mission-critical environments.

16:07 EDT United Airlines backs FY24 adjusted CapEx 'less than' $6.5B - The company is targeting net leverage below 2x in the next few years.

16:06 EDT United Airlines reports Q3 ending available liquidity of $17.1B - Total debt and finance lease obligations of $25.7B at quarter end. Net leverage of 2.7x.

16:05 EDT United Airlines announces $1.5B share repurchase program - The company's Board of Directors authorized a new share repurchase program for up to $1.5B of outstanding shares of common stock and warrants originally issued to the U.S. Treasury under the CARES Act and Payroll Support Program, subject to a limit of $500M in aggregate through year-end 2024. This amount represents approximately 7% percent of the company's market capitalization based on the closing stock price on Oct 14, 2024. This is the first share repurchase program since the suspension of the previous program in 2020 due to the COVID-19 pandemic. Unless suspended or terminated earlier by our Board of Directors, this program has no set expiration date and will therefore terminate when the company has completed all purchases authorized under the program.

16:03 EDT VSE Corp. acquires Kellstrom Aerospace for $200M - VSE Corp. "announced that the Company has signed a definitive agreement to acquire Kellstrom Aerospace Group, Inc., a portfolio company of AE Industrial Partners, LP and a diversified global distributor and service provider supporting the commercial aerospace engine aftermarket. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the fourth quarter of 2024. The contract is for total consideration of approximately $200 million, comprised of approximately $185 million in cash and approximately $15 million of shares of common stock of the Company, subject to working capital adjustments. Kellstrom generated approximately $175 million of revenue during the trailing twelve months through August 2024. Kellstrom deal is expected to generate synergies of approximately $4M."

16:03 EDT United Airlines reports Q3 capacity up 4.1% y/y - In Q3: Capacity up 4.1% compared to third-quarter 2023. Total operating revenue of $14.8 billion, up 2.5% compared to third-quarter 2023. TRASM down 1.6% compared to third-quarter 2023. CASM up 0.1%, and CASM-ex1 up 6.5%, compared to third-quarter 2023.

16:01 EDT United Airlines announces $1.5B share repurchase program

14:47 EDT Trump Media trading resumes

14:02 EDT Exelixis 'pleased with the court's ruling' in trial with MSN Laboratories - Exelixis announced that in the lawsuit Exelixis, Inc. vs. MSN Laboratories Private Limited et al., Civil Action No. 22-00228, the U.S. District Court for the District of Delaware ruled in Exelixis' favor, rejecting MSN's challenge to three Orange Book-listed patents related to cabozantinib, including U.S. Patents No. 11,091,439; 11,091,440; and 11,098,015. The District Court's decision in Exelixis' favor on the validity of these patents follows an earlier Stipulation entered on June 21, 2022, that MSN's proposed generic cabozantinib product infringes the '439, '440, and '015 patents, which expire on January 15, 2030. Additionally, the court ruled that Exelixis' pharmaceutical composition patent, U.S. 11,298,349, is not invalid and not infringed by MSN's proposed ANDA product. "We are pleased with the court's ruling, which upheld the validity of Exelixis' '439, '440, '015 and '349 patents. We remain confident in the strength of the current and emerging cabozantinib patent estate. We will continue to pursue every available legal action to defend our intellectual property rights, which are crucial to safeguarding the scientific innovation that drives our mission to help cancer patients recover stronger and live longer," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. "MSN is seeking approval for a product containing a different polymorphic form of cabozantinib (l)-malate than the form contained in Exelixis' breakthrough CABOMETYX product. To Exelixis' knowledge, the U.S. Food and Drug Administration has not yet granted tentative approval of that potential product. If the FDA ultimately approves MSN's ANDA, given today's decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the U.S. is January 15, 2030, subject to any appeals or additional regulatory exclusivity," the company added.

13:55 EDT Genius Group LTD trading resumes

13:10 EDT Genius Group LTD trading halted, news pending

12:54 EDT Roblox launches 5-month program 'Roblox Teen Council' - Roblox said on X that, "We're officially launching the first ever Roblox Teen Council! This 5-month program in the U.S. is designed for us to collaborate and hear from teens on platform features, online safety, and digital well-being. Applications close Dec 6."Reference Link

12:22 EDT ASML: Q3 results published early due to technical error - ASML said that due to a technical error, information relating to its Q3 results was erroneously published earlier today on part of its website. For transparency, ASML brought forward publication of its full Q3 results to October 15 and all Q3 content is available on its website.

12:21 EDT Uber introduces Uber Business Black - Corporate travelers expect more out of their business travel: more comfort, more legroom, more flexibility, and more support. That's why Uber for Business is introducing Uber Business Black, a new ride type designed to meet this growing demand for premium travel experiences. "Uber Business Black reimagines the traditional black car experience, combining the luxury of premium car services with the flexibility, familiarity, and ease of Uber. Now, corporate travelers and their executive assistants can use Uber Reserve to schedule Uber Business Black rides in advance-setting the entire travel itinerary at once-or use the Uber app to request a black car on-demand if their schedule is uncertain or a last-minute change pops up." Reference Link

12:07 EDT LVMH drops 10% to $125.91 after Q3 sales report

12:02 EDT Direxion Daily Semiconductor Bear 3X Shares rises 12.0% - Direxion Daily Semiconductor Bear 3X Shares is up 12.0%, or $2.15 to $20.07.

12:02 EDT VeriSign Inc falls -9.4% - VeriSign Inc is down -9.4%, or -$13.28 to $128.67.

12:00 EDT Direxion Daily Semiconductor Bull 3X Shares falls -11.7% - Direxion Daily Semiconductor Bull 3X Shares is down -11.7%, or -$4.78 to $36.05.

11:50 EDT Cineverse says 'Terrifier 3' opened to $21.4M in holiday weekend box office - Cineverse reports that with over 2,500 theaters in North America, "Terrifier 3" opened to $21.4M at the box office over the four-day holiday weekend. "This isn't just a triumph for Cineverse, it's a victory for independent filmmakers everywhere," said Chris McGurk, Chairman & CEO of Cineverse. "Terrifier 3 shows that with the right creative team and the support of loyal fans, a quality indie film can break the mold and compete with major studio releases. We're beyond thrilled with the reception, and this success proves that Damien and Phil's connection to horror fans is second to none."

11:42 EDT ASML sinks 16% to $728.73 following Q3 report

11:22 EDT NRF says steady sales growth expected for 2024 holiday season - The National Retail Federation forecasts that winter holiday spending is expected to grow between 2.5% and 3.5% over 2023. That equates to between $979.5B and $989B in total holiday spending in November and December, compared with $955.6 billion during the same timeframe last year. "The economy remains fundamentally healthy and continues to maintain its momentum heading into the final months of the year," NRF President and CEO Matthew Shay said. "The winter holidays are an important tradition to American families, and their capacity to spend will continue to be supported by a strong job market and wage growth." The holiday forecast is consistent with NRF's forecast that annual sales for 2024 will be between 2.5% and 3.5% over 2023. A primary contributor of overall retail sales growth is expected from online shopping. Online and other non-store sales, which are included in the total, are expected to increase between 8% and 9% to a total of between $295.1B and $297.9B. This figure is up from $273.3B last year. By comparison, last year non-store sales rose 10.7% over 2022. As retailers anticipate increased consumer demand during the holiday season, additional associates are needed to support business operations. NRF expects retailers will hire between 400,000 and 500,000 seasonal workers this year, some of which may have been pulled into October to support retailers' holiday buying events this month. This compares with 509,000 seasonal hires last year.Reference Link

11:18 EDT Citi will spend whatever is needed to address regulatory fixes

11:16 EDT Citi expects to be at higher end of $53.5B-$53.8B expense guidance for FY

11:12 EDT Citi plans to repurchase stock, says CEO

11:11 EDT Citi: Clients pulled forward activity before U.S. election - CEO Jane Faser says clients reducing payments, increasing interest bearing balances.

11:05 EDT Exelixis trading resumes

11:02 EDT Donaldson announces new distribution center in Olive Branch, Mississippi - Donaldson Company announces the opening of its newest distribution center in Olive Branch, Mississippi. This new facility will further strengthen Donaldson's ability to meet growing customer demand in the mobile solutions aftermarket business, including the heavy-duty trucking, construction, mining, and agricultural equipment sectors. The Olive Branch distribution center, located in the Memphis, Tennessee metropolitan area, will provide an additional 200,000 square feet of warehousing space to Donaldson's distribution center footprint. Adding this new facility will provide the necessary room for the growth of the business while also providing the opportunity to further enhance the capabilities at the primary distribution center in Rensselaer, Indiana.

10:59 EDT Walgreens sees closing about 1,200 store over next three years - Earlier, along with Walgreens Boots Alliance having announced financial results for the fiscal year and fourth quarter that ended Aug. 31, the company announced a footprint optimization program targeting approximately 1,200 closures over the next three years, including approximately 500 closures in fiscal 2025, which it says "will be immediately accretive to adjusted EPS and free cash flow." Future expected store closures of approximately 1,200 includes approximately 300 stores previously approved under the "Transformational Cost Management Program," the company noted.

10:17 EDT PNC Financial says on track to generate FY24 positive operating leverage - Says continues to be 'well-positioned' in capital flexibility. Says 'remains diligent' in continuous improvement efforts. Says continues to see stress in the office portfolio. Says expects continued economic growth in Q4. Says expects Fed to cut rates two additional times in 2024.

10:09 EDT Goldman sees deal to transfer GM credit card partnership closing in 3Q25

10:01 EDT BAE Systems awarded up to $460M contract from U.S. Army - The U.S. Army has awarded BAE Systems a five-year indefinite delivery, indefinite quantity contract with a ceiling value of $460M for the AN/ARC-231/A Multi-mode Aviation Radio Set. This award consists of hardware components, repair services, engineering and logistic support, and development for rotary-wing aircraft. The MARS system is designed to perform in the most demanding environments to provide warfighters with secure mission-critical information when they need it most.

10:00 EDT Charles Schwab rises 8.1% - Charles Schwab is up 8.1%, or $5.50 to $73.32.

10:00 EDT Ameresco falls -7.3% - Ameresco is down -7.3%, or -$2.56 to $32.38.

10:00 EDT Coty falls -9.3% - Coty is down -9.3%, or -85c to $8.32.

09:48 EDT Carnival rises 5.5% - Carnival is up 5.5%, or $1.12 to $21.33.

09:48 EDT Wolfspeed rises 37.5% - Wolfspeed is up 37.5%, or $4.26 to $15.64.

09:47 EDT Dingdong falls -7.3% - Dingdong is down -7.3%, or -24c to $3.03.

09:37 EDT Knightscope announces three expansion contracts for ECDs - Knightscope announces three new expansion contracts for its Emergency Communication Devices and other long-term ECD services provided by Knightscope. A law school in Vermont added the Knightscope Emergency Management System program for 2 of its K1 Blue Light Towers; a Pennsylvania university purchased an additional K1 Blue Light Tower; and a university in southern California renewed its Full Service Maintenance Plan for all Knightscope ECDs on campus.

09:36 EDT Goldman continues to have 'concerns' about regulatory process over capital rules

09:35 EDT PNC Financial sees Q4 revenue stable vs. Q3, consensus $5.49B - Sees Q4 average loans stable; NII up about 1%; Fee income down 5%-7%; Other noninterest income $150M-$200M; Core noninterest expense up 2%-3%; Net charge offs about $300M. All Q4 guidance vs. Q3. Comments taken from investor presentation slides for Q3 earnings conference call.

09:34 EDT Goldman Sachs sees 2024 alternatives fundraising exceeding $60B, says CEO

09:32 EDT Genprex approved to advance to highest dose in Phase 1 lung cancer trial - Genprex has completed the 0.09 mg/kg dose group of the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy in combination with Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer. In addition, the Safety Review Committee has approved escalation to the highest dose group of 0.12 mg/kg. The combination of REQORSA and atezolizumab previously received FDA Fast Track Designation for the treatment of the Acclaim-3 patient population and the FDA has also granted Orphan Drug Designation to Reqorsa for the treatment of SCLC. There were no dose limiting toxicities in this dose group and the SRC recommended moving up to the highest dose group planned in the trial. The first patient treated in the Phase 1 dose escalation portion of the Acclaim-3 trial had a partial remission from prior to the start of maintenance therapy to the time of the CT scan performed after two cycles of maintenance therapy. The company believes this suggests that Reqorsa may be providing clinical benefit. The primary endpoint of the Phase 1 escalation portion is to determine the maximum tolerated dose or recommended Phase 2 dose. After the Phase 1 portion is complete, the Phase 2 expansion portion will enroll 50 patients at 10 to 15 U.S sites.

09:28 EDT Critical Metals advances development of Tanbreez Rare Earth Mine - Critical Metals provided a project update for the Tanbreez Greenland Rare Earth Mine. The Tanbreez Project has been granted an extension for its Exploitation License from the Greenland Cabinet of Ministers and the Company completed its recently announced diamond drilling program. The Greenland Government has granted an extension to certain deadlines under the Exploitation license of the Tanbreez Project 2028. Under the new amendment, Tanbreez Mining Greenland A/S is required to submit its exploitation and closure plans by the end of 2025, provide financial security and a company guarantee by June 30th, 2026, and commence the exploitation of minerals by the end of 2028. With the drilling program concluded, all rare earth material extracted has been safely secured in storage. A portion of the rare earth material extracted has been sent to be analyzed by ALS laboratory in Ireland. Critical Metals Corp expects to receive the test results over the next several months.

09:24 EDT Metal Sky Star Acquisition enter LOI with Fedilco Group - Metal Sky Star Acquisition Corporation has entered into a letter of intent with Fedilco Group Limited, a Cyprus based company holding 80% equity interest of Viva Armenia Closed Joint-Stock Company, an Armenia-based telecommunication company. Pursuant to the LOI, the Company expresses interest in acquiring all the issued and outstanding shares of Fedilco. The parties will obtain all the required permissions and/or approvals of the state authorities of the Republic of Armenia. Viva's success in the field of mobile communications is conditioned by the following principle: mobile services should be available not to a limited number of people, but to everyone. Viva provides its subscribers with the opportunity to keep in touch with their homeland, regardless of their location. Viva has 529 roaming partners in 192 countries of the world. Viva is the first company in Armenia to introduce and apply CSR as a management model and is the first operator to be guided by the international principles of social responsibility ISO 26000.

09:22 EDT HealthEquity launches HSAnswers AI tool - HealthEquity in celebration of National HSA Awareness Day, has launched HSAnswers. Powered by a comprehensive and bespoke database of resources, research, and insights, the free-to-use AI chat tool can help individuals obtain clear answers to questions about HSAs and other consumer-directed benefits. In 2024 HealthEquity surveyed over 600 employees who said their top benefits challenge was being overwhelmed by the amount of information available to them. HSAnswers helps provide the extra support employees are asking for by serving up the answer for them without them having to dig through a mountain of information. HSAnswers offers instant, educational information about HSAs and other benefits.

09:22 EDT Helios opens two of three Sun Hydraulics' manufacturing facilities in Sarasota - Helios Technologies provided an update on its recovery efforts from Hurricane Milton. "I am so grateful that we did not have any reported injuries or loss of life within our team, as Sarasota was directly hit by the hurricane," said Sean Bagan, Interim President, Chief Executive Officer, and Chief Financial Officer of Helios...Our goal was to be up and running as quickly as possible to support our customers. We are very pleased to announce the reopening of two of our three Sun Hydraulics' manufacturing facilities in Sarasota as of today, only six days after this Category 3 hurricane made landfall." "We will not have our full capacity online until we reopen our third facility, which sustained more extensive damages. The team is working diligently to fully recover. We are also assessing any hurricane impacts from regional suppliers, freight carriers, and infrastructure disruption. I am incredibly proud of how our local Sun Hydraulics team worked tirelessly, with support from our global Helios businesses, as we recover from this weather-driven disaster. It is a testament to the incredible people that we have in our organization and the shared values that we all live by every day," said Rick Martich, President of Hydraulics, Americas of Helios. The Company plans to provide its estimates of the effects of Hurricane Milton on its fourth quarter financial projections when it reports its upcoming third quarter 2024 financial results.

09:21 EDT Meritage Homes appoints Lantz as an independent director - Meritage Homes announced the appointment of Erin Lantz as an independent director to its Board of Directors, effective October 14, 2024. Her appointment demonstrates the Company's commitment to ongoing board refreshment as it increases its size to 11 directors. The Board plans to consider Lantz for appointment to one or more board committees over the course of the next several regularly scheduled board meetings.

09:21 EDT Blink Charging announces strategic agreement with Stable Auto - Blink Charging has announced a strategic agreement with Stable Auto to optimize Blink's charging network and contributions to EV infrastructure. Stable provides AI-powered solutions to help organizations strategically plan and operate EV charging networks. By analyzing utilization trends from tens of thousands of public EV chargers across the U.S., Stable's software delivers insights that help minimize deployment risks and manage profitability. "This collaboration marks a significant milestone in enhancing the accessibility and efficiency of our charging solutions," said Mike Battaglia, Chief Operating Officer and CEO-Elect at Blink. "We have already experienced the staying power of utilizing this platform. For example, we achieved a 34% improvement in efficiency, increasing the net revenue across 60 locations. Blink has always maintained a 'right charger, right place, right time' mindset, allowing us to proactively meet the growing infrastructure demands of every kind of EV driver."

09:20 EDT Frontier Communications stockholder Cooper Investors issues letter - Frontier Communications (FYBR) significant stockholder Cooper Investors, an Australia-based global investment manager, issued an open letter to the board of directors of Frontier in which it expressed its strong opposition to the acquisition of Frontier by Verizon (VZ) for $38.50 per share. In the letter, Cooper Investors expressed its belief that the standalone value of Frontier is as much as 62% higher than Verizon's offer price and that the fair transaction value would be up to 94% higher. Cooper Investors stated its intention to vote against approval of the Proposed Transaction and encouraged its fellow stockholders to do the same at the company's upcoming special meeting of stockholders scheduled to be held on November 13. [Letter to Frontier Board]:[https://assets-oce.mkt.dynamics.com/af3e6cd2-3d4e-4fb2-bc6a-2ce71c0f07b2/digitalassets/docs/26b9523d-cb8a-ef11-8a6a-6045bde66c86?ts=638645759100000000]

09:19 EDT Methes Energies appoints Kenneth Lukins to board of directors - Methes Energies announced the appointment acceptance of Chief Kenneth Lukins, US Coast Guard to the company's Board of Directors. In addition to accepting his appointment, Mr. Lukins' current roles include Managing Director of Lukins International and Vice Chairman of the Climate Change Forum.

09:18 EDT Red Cat secures $1M contract for its FlightWave Edge 130 Blue - Red Cat Holdings announced it secured a $1M contract for its Edge 130 Blue drones from the United States Army Communications-Electronics Command, CECOM. The contract was secured through Noble, a leading provider of global sustainment and operations support for the U.S. Military and civilian government agencies, and was coordinated for procurement by the U.S. Defense Logistics Agency, DLA, on behalf of CECOM.

09:16 EDT G2 Goldfields announces multiple new gold zones discovered at OKO project - G2 Goldfields provided an update on its ongoing exploration program at the Company's 58,000-acre OKO-Aremu gold project, Guyana. G2 currently has five rigs operating at the project, building on the Company's current mineral resource which is comprised of 922,000 ounces of gold and 1,099,000 ounces. G2 continues to expand and define existing gold zones whilst discovering new high grade parallel zones of gold mineralization. The Company intends to issue an updated resource estimate for the OKO project in Q1 of 2025. G2's OKO gold resource lies along a prominent 2.5-kilometre-long north-south structure which is defined by the high grade OMZ resource to the north and the Ghanie open pit and underground resource to the south. G2 is currently drilling in the Ghanie Zone, the southern half of the structure. This drilling is targeting: expansion of near surface-open-pittable deposits along strike, expansion of existing pittable mineralization to depths greater than -350m, extensions of high-grade Ghanie mineralization at depth, possible parallel zones of mineralization to the east of the main Ghanie Zone, and extensions to shear hosted high grade gold associated with the OKO Main Zone

09:15 EDT Cipher Mining signs agreements to acquire three sites from Juvo Energy - Cipher Mining announced it has signed option agreements to acquire the recently announced three sites in West and North Texas from Juvo Energy. The three sites are adjacent to transmission assets and in the final stages of approval for interconnection with 500 MW targeted capacity per site. Cipher will be able to exercise the option in the next 24 months to acquire the sites, including 580 acres of land to be either leased or purchased. The ultimate purchase price to exercise the options for the sites will be determined by the number of megawatts actually approved for interconnection. The three sites all have the necessary characteristics for development of HPC data centers or bitcoin mining operations.

09:14 EDT Tetra Tech awarded $37.5M USAID urban water, waste services deal - Tetra Tech announced that the U.S. Agency for International Development USAID has awarded the Company a $37.5M single-award contract for 5 years to increase access to safe and reliable water, sanitation, and solid waste management services for urban communities in Southern Africa. Tetra Tech has partnered with USAID to improve access to safe, sustainable water supplies in developing countries for more than 40 years," said Dan Batrack, Tetra Tech Chairman and CEO. "We look forward to using our Leading with Science approach to support the people of the Limpopo River basin in creating more resilient urban communities."

09:13 EDT Apple introduces new iPad mini - Apple introduced the new iPad mini, powered by the A17 Pro chip and Apple Intelligence, the personal intelligence system that understands personal context. The new iPad mini is available in four colors, including a new blue and purple, and features the 8.3-inch Liquid Retina display.

09:11 EDT FuboTV and The Athletic in multi-year content and product integration deal - FuboTV and The Athletic announced an in-depth partnership making Fubo the official live TV streaming partner of The Athletic. The multi-year agreement incorporates content and product integrations as well as plans to co-market the two brands to their respective audiences. Fubo will be integrated into live game blogs and additional content on The Athletic's leading sports platform as a go-to sports streaming destination. As part of this, The Athletic will work with Fubo to provide the most engaging and informative content experience possible through custom in-content modules that will feature relevant game information. The Athletic and Fubo plan to jointly develop new product features on The Athletic platform designed to ultimately build a unique and market-leading user experience. "The Athletic is one of the most trusted sources in sports media and we have a shared passion of building community through sports at local and national levels," said Yale Wang, executive vice president of marketing, Fubo. "We are excited to be The Athletic's first official streaming partner and look forward to connecting with sports fans through bold new integrations while providing leading sports coverage."

09:10 EDT Paylocity debuts AI Assistant to simplify, accelerate HR processes - Paylocit announces AI Assistant, a conversational AI-driven assistant designed to streamline HR processes and elevate the employee experience. Building on Paylocity's long-standing AI-driven capabilities, the Paylocity AI Assistant simplifies HR-related tasks with real-time, contextual support across the Paylocity platform. This innovation empowers HR professionals to navigate processes with ease and will deliver intuitive, personalized assistance to end-user employees.

09:10 EDT Danimer Scientific names Richard Altice as interim CEO - Danimer Scientific announced that Richard Altice, a current Danimer director and former president and CEO of NatureWorks, has been named interim CEO, effective immediately. Altice succeeds Stephen Croskrey, who previously announced his intention to retire after more than eight years as CEO. In addition to his ongoing role as a director, Croskrey has agreed to serve as a special advisor until the end of the year to further support this transition. Richard Hendrix will continue to lead the board as chairman. As previously announced, the board has formed an executive committee charged with leading the search process for a permanent CEO, along with oversight of strategy and shareholder engagement during the transition period. The executive committee has made significant progress on its search, which includes internal and external candidates, and has retained a nationally recognized executive search firm to support the process. In connection with today's announcement, Altice will replace Croskrey on the executive committee, which also includes directors Hendrix, John Amboian, and David Moody.

09:09 EDT CarGurus launches new campaign with former NFL quarterback Drew Brees - CarGurus launched a new campaign with former NFL quarterback Drew Brees focused on helping today's drivers feel even more confident and prepared during the car buying and selling process. "Known for his rigorous mental and physical preparation during his professional football career, Drew's winning combination of steady confidence and rigorous research both on and off the field makes him the perfect confidence coach for today's drivers, and a natural partner for CarGurus," said Dafna Sarnoff, CarGurus Chief Marketing Officer. "Car shoppers can identify with Drew's mindset of gathering the best information and tools available to feel confident that they are getting the best deals for their unique individual needs."

09:08 EDT Medirom Healthcare subsidiary formed capital, business alliance with Elematec - MEDIROM Healthcare Technologies announces that its subsidiary MEDIROM MOTHER Labs has formed a capital and business alliance with Elematec Corporation, a member of the Toyota Tsusho Corporation group. Under the capital and business alliance agreement, Elematec Corporation has agreed to make a strategic investment in MEDIROM MOTHER Labs' Series A round at a pre-money valuation of 9 billion yen.

09:07 EDT PG&E Board Chair Robert Flexon stepping down, Kerry Cooper to succeed - PG&E announced today that effective October 31, current Board Chair Robert Flexon is taking a CEO role at another utility company and consequently will be leaving the PG&E and Utility Boards. He has been on both PG&E boards since 2020 and earlier served as President and CEO at Dynegy. Kerry Cooper has been elected by the PG&E Corporation Board of Directors as its new Chair, effective October 31. Cooper has been on both the PG&E Corporation and Utility Boards of Directors since 2020. Cooper served as CEO at Choose Energy, as President and COO at retail company Rothy's, and in leadership roles at Walmart and Levi Strauss.

09:06 EDT Tenable announces new DSPM, AI-SPM capabilities for Tenable Cloud Security - Tenable announced new data security posture management, DSPM, and artificial intelligence security posture management, AI-SPM, capabilities for Tenable Cloud Security, the actionable cloud security solution. By extending exposure management capabilities to cloud data and AI resources, Tenable Cloud Security reduces risk to two of the biggest emerging threats.

09:04 EDT Myriad Genetics, Flatiron partner to make genetic testing more accessible - Myriad Genetics announced a collaboration with Flatiron Health. This collaboration allows physicians to order Myriad's MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron's cloud-based Electronic Medical Record, EMR, platform, OncoEMR. MyRisk is the first hereditary cancer test to be incorporated into Flatiron's OncoEMR. The integration allows 4,200 providers at over 800 community-based cancer care locations across the U.S. in Flatiron's network to conveniently order, receive, and review MyRisk testing results directly through their daily OncoEMR system.

09:03 EDT Micron launches Crucial DDR5 clocked unbuffered dual inline memory modules - Micron Technology announced the availability of a brand-new category of clock driver memory with the launch of its Crucial DDR5 clocked unbuffered dual inline memory modules and clocked small outline dual memory modules, which are now shipping in volume. The JEDEC-standard solutions run at speeds up to 6,400 MT/s, more than twice as fast as DDR41 and 15% faster than traditional non-clock-driver-based DDR5.2 Designed to provide more speed stability, faster downloads and better refresh rates, these solutions represent a completely new frontier of memory form factors for next-generation PCs. Micron's CUDIMM and CSODIMM solutions are the industry's first commercially available JEDEC-standard DDR5 CUDIMM and CSODIMM solutions to hit the market since JEDEC standardized the specification earlier this year.

09:02 EDT Johnson & Johnson says continues to invest in R&D at 'competitive levels' - Expects "elevated levels" of investment in Q4. Expects "no material improvement" in Asia Pacific region for remainder of year. Says "making progress" towards resolution of talc litigation, but no update on timeline. Says capital allocation strategy "remains unchanged." Sees 2025 tax rate "slightly lower" than 2024.

08:59 EDT BofA: 100bp rate cut would hurt NII by $2.7B in a year

08:57 EDT Safe and Green Development receives permits to begin construction in South Texas - Safe and Green Development announced that all site work has been completed for the first phase of its Sugar Phase I project in South Texas. The company has completed the work of resurfacing the lots to receive the necessary elevation certificates to move forward with vertical construction. The company has now received all necessary permits. The company expects to deliver the first phase of homes by Q1 2025 and to be able to sell all homes to Trio, as Program Administrator for Choctaw American Insurance, within that quarter.

08:56 EDT Gaucho Group's Algodon Fine Wines unveils newest vintages in the U.S. - Gaucho Group Holdings' Algodon Fine Wines has launched its collection of newest vintages in the United States. These exceptional wines, made from hand-harvested grapes grown in the vineyards of Algodon Wine Estates, beautifully capture the distinctive terroir of Argentina's renowned San Rafael region. Highlighting Algodon's celebrated Malbec and exclusive Malbec blends, the 2024 collection embodies the rich, bold flavors and sophisticated elegance that have become synonymous with Algodon Fine Wines. This collection includes the newest vintages of its estate range of wines such as Algodon Estate Malbec 2022, Algodon Estate Bonarda 2022, Algodon Estate Chardonnay 2023, as well as its microvinified black label range of wines such as Cabernet Fran-Malbec Reserve 2020, Gran Cuvee 2021, PIMA 2021, and brand new, never-before seen stateside wines such Algodon's Chardonnay-Pinot Noir 2022, Cabernet Franc Reserve 2020, and its Winemaker's Selection 2021. The latter three wines are slated to be introduced to Algodon's customers through digital media and announcements over the next week.

08:54 EDT Four Nines announces grand openings in San Antonio - Four Nines announced the grand opening of its newest two stores in San Antonio, Texas, at 8597 Blanco Road and 17641 Bulverde Road. The Bulverde store had a soft opening over the past couple of weeks, and both stores will officially open their doors on Tuesday, October 15th, bringing a fresh and unique shopping experience to the local community.

08:51 EDT Bank of America doesn't see much change in headcount for Q4, says CFO

08:50 EDT Sidus Space gets FCC approval for expanded on-orbit presence - Sidus Space announced that the U.S. Federal Communications Commission FCC has granted approval for the company to operate a micro constellation of remote sensing, multi-mission satellites in Low Earth Orbit LEO. This key regulatory milestone marks a significant step in Sidus Space's on-orbit expansion plans and reinforces its strategic commitment to enabling new missions and delivering flexible, cost-effective data acquisition solutions through its innovative data-as-a-service model. Sidus owns the data collected by LizzieSat Sidus sensors for all missions, providing customers with a distinct advantage in accessing valuable data streams...The FCC approval represents a major advancement for Sidus Space as it continues to grow its on orbit presence and to enhance its ability to serve a wide range of industries with expanded real-time, space-based data services.

08:50 EDT Peraso says Miliwave announces MWC-932 product added to AirPath 60 line - Peraso is pleased to announce that Miliwave announced at WISPAPALOOZA its MWC-932 product as an addition to its AirPath 60 product line. Miliwave's AirPath products use Peraso's Perspectus mmWave modules with Peraso's X720 chipset. Utilizing the unlicensed 60 GHz band, the MWC-932 provides a wireless Ethernet Bridge for applications which require multi-gigabit throughput. Miliwave's latest solution is designed to be immune to interference from common Wi-Fi and to provide a robust link at distances up to 5km. The high-gain, offset-parabolic antenna is fully enclosed and weather protected in order to maintain performance during ice and snow conditions. The compact radio is only 114mm x 145mm x 125mm.

08:48 EDT Pfizer, TRIANA enter research collaboration - TRIANA Biomedicines has entered into a strategic collaboration and licensing agreement with Pfizer to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.Under the terms of the collaboration agreement, TRIANA will receive an upfront payment of $49 million, and is eligible to receive potential future milestone payments exceeding $1.5 billion as well as tiered royalties. TRIANA will leverage its target-first and proximity-first molecular glue discovery platform to identify novel molecular glue degraders against multiple targets across various disease areas including oncology. TRIANA will lead the discovery and identification of potential development candidates. Pfizer has the exclusive option for an exclusive license to pursue further preclinical and clinical development.

08:47 EDT Elliott launches 'Stronger Southwest' podcast - Elliott Investment Management L.P., which manages funds that together have an investment representing an approximately 11% economic interest in Southwest Airlines, announced the launch of Stronger Southwest, a new podcast series that will feature 1:1 conversations with Elliott's highly qualified director nominees. Episodes can be accessed on StrongerSouthwest.com, and are available on Apple, Spotify and everywhere podcasts are heard. You can not only listen to the conversations on all major podcast feeds, but also can watch the episodes on YouTube. Yesterday, Elliott called for a December 10 special meeting of shareholders, seeking the election of eight best-in-class nominees to serve on Southwest's Board. Today's launch of an innovative new podcast series will offer shareholders an opportunity to learn more about these uniquely qualified nominees. The first episode features Nominee Gregg Saretsky, who has significant leadership and industry experience stemming from his nearly 40-year career in aviation. Mr. Saretsky discusses his early years in the industry, "where the aviation fuel got in [his] blood," as well as lessons learned from his time as CEO of WestJet - among other roles - and the high-value potential he believes can be delivered at Southwest,.

08:46 EDT Accuray CEO Suzanne Winter returns from medical leave of absence - Accuray announced that CEO Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and CEO. Sandeep Chalke, who has served as interim CEO during Winter's absence, will continue in his position as Senior VP and COO.

08:44 EDT Ads-Tec Energy announces Stefan Berndt-von Bulow to assume CFO role - ADS-TEC Energy is moving forward with its planned organizational evolution. Wolfgang Breme has played a role as CFO. In line with its strategic succession plan, ADS-TEC Energy is pleased to announce that the planned CFO transition, originally set for 2025, has been accelerated. Stefan Berndt-von Bulow will assume the role of CFO for ADS-TEC Energy PLC and its subsidiaries, effective October 14. Berndt-von Bulow brings experience as a CFO, with a background in high-tech product portfolios, growth-oriented organizations, and capital markets.

08:43 EDT Bank of America CFO says liquidity remains strong

08:42 EDT Bank of America expects to move to operating leverage in 2025, says CEO

08:41 EDT Banzai has engaged MZ Group to lead an IR, financial communications program - Banzai International has engaged international investor relations specialists MZ Group to lead a comprehensive strategic investor relations, IR, and financial communications program across all key markets. MZ Group will work closely with Banzai's management team to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight that Banzai is consolidating mission-critical, sub-scale marketing technology products to build a data-driven platform of solutions that seamlessly integrate out of the box.

08:39 EDT Microbot announces it completed enrollment, follow p for ACCESS-PVI trial - Microbot Medical announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial. The Company remains on track to file its 510(k) submission with the U.S. Food and Drug Administration, FDA, by of the end of 2024. The Company also announced that it is accelerating its go-to-market strategy. It expects to begin building out the commercial infrastructure, including the hiring of a seasoned healthcare executive to lead its sales efforts, upon the FDA clearance, which is expected during 2Q 2025. "We are very pleased with the performance of LIBERTY(R) throughout the study," commented Juan Diaz-Cartelle, MD, Chief Medical Officer. "We want to thank all our investigators for their enthusiastic commitment to the trial. We expect to share the results of the clinical trial with the medical community and the public at a conference in early 2025."

08:39 EDT Johnson & Johnson says shifting pipeline to high innovation, high growth markets - Says "confident" in expectations for 2025 and beyond. Comments taken from Q3 earnings conference call.

08:38 EDT Telos expands enrollment, renewal options by opening twelve locations - Telos Corporation continues to expand locations to enroll consumers in the TSA PreCheck program by opening twelve new locations in California, Colorado, Indiana, Mississippi, Missouri, Oregon, Texas and Washington. These locations began offering enrollment services on October 14, 2024. Telos now has 149 TSA PreCheck enrollment centers open in 28 states across the U.S. The launch of these new enrollment centers represents the ongoing expansion of Telos' national TSA PreCheck enrollment footprint. Throughout 2024, Telos will continue delivering convenience to consumers by launching additional locations and extended hours of operation for enrollment and renewals.

08:37 EDT DataBank announces ~$2.0B equity raise - DataBank announced a $2.0B equity raise led by AustralianSuper, Australia's largest superannuation fund, which committed $1.5B. Upon closing of the transaction, AustralianSuper will become a significant minority owner of DataBank and will join the company's board of directors. The capital raise was oversubscribed and, in addition to the $1.5B from AustralianSuper, included another $483M in commitments from existing investors. The investment in DataBank would be AustralianSuper's first in the U.S. data center market and the second alongside existing DataBank investor DigitalBridge. AustralianSuper's global real assets portfolio now totals nearly $40B, and includes digital infrastructure assets across Australia, EMEA and South America.

08:36 EDT Astronics CFO David Burney to retire, Nancy Hedges to succeed - Astronics announced that its board of directors has appointed Nancy Hedges, currently controller and principal accounting officer, to VP and CFO effective upon the retirement of David Burney, the company's current CFO, on January 3, 2025. Nancy Hedges joined Astronics in 2014 as principal accounting officer and controller.

08:35 EDT Bank of America expects NII to grow again in Q4, says CEO - Comments taken from Q3 earnings conference call.

08:34 EDT Foot Locker signs multi-year partnership with Chicago Bulls - Foot Locker announced a multi-year partnership with the Chicago Bulls ahead of the 2024-25 NBA season. This partnership will feature community basketball events, exclusive in-store activations, and behind-the-scenes player-focused content. Foot Locker will engage the Bulls fanbase through initiatives including: community basketball events such as Bulls Fest, a Youth Hoops 3v3 Tournament presented by Foot Locker, community-focused events at its Chicago stores; in-store activations such as on November 2nd, when Foot Locker's State Street location will host a Bulls celebration, featuring player meet-and-greets and live entertainment; exclusive Tunnel Walk content on social media, offering fans behind-the-scenes access to their favorite players as they prepare to take the court. Both organizations will launch of their partnership on Oct. 30 during the Bulls game vs. Orlando. The game night will include a pregame event in the Atrium featuring photo opportunities, skills and drills activities, and giveaways, as well as a Youth 3v3 exhibition game at halftime.

08:34 EDT scPharmaceuticals to host KOL webinar on FUROSCIX use - scPharmaceuticals will host a KOL webinar focused on a nephrologist's perspective on the use of FUROSCIX for treating fluid overload in heart failure and potential use for patients with chronic kidney disease on Tuesday, October 22, 2024 at 1:00 PM. The event will feature Dr. Michael Aaronson, MD. The FDA has assigned a PDUFA target action date of March 6, 2025, to consider scPharmaceuticals' Supplemental New Drug Application seeking to expand the FUROSCIX indication to include the treatment of fluid overload in CKD. scPharmaceuticals' management will also provide a corporate update focused on the company's long-term growth initiatives, including the FDA-approved expansion of the FUROSCIX indication to include New York Heart Association Class IV heart failure patients, the potential expansion of the FUROSCIX indication to include treatment of fluid overload in CKD patients, and the ongoing development of a low volume autoinjector designed to provide physicians and patients with additional treatment flexibility.

08:32 EDT Alto Ingredients provided updates on its Magic Valley facility in Idaho - Alto Ingredients provided updates on its Magic Valley facility in Idaho where it has installed Harvesting Technology's patented system to capture its high protein and corn oil products. For October to date, the new equipment and system modifications to improve capacity at the Magic Valley facility are delivering the following metrics: Average renewable fuel production rates at full production capacity while operating the high protein and corn oil technology systems; Protein content at 50% or greater, with improved protein production yields of over three pounds per bushel, diversifying the facility's product mix with a higher margin offering; and Corn oil yields are improving and are expected to increase further as Alto continues aligning systems and operations.

08:29 EDT Arbutus Biopharma announces abstracts highlighting imdusiran data - Arbutus Biopharma announced that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases - The Liver Meeting 2024, scheduled from November 15-19, 2024 in San Diego, CA. This includes two late-breaking posters with imdusiran data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials. Presentation Title: Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon Alfa Reveals Phases of Immune Activation: Key Findings: Imdusiran treatment in combination with IFN was associated with distinct phases of soluble immune biomarker signatures. Immune biomarkers associated with Th1 immune activation and regulation of inflammation were observed in subjects during imdusiran lead-in, coinciding with the establishment of a plateau in HBsAg reduction. Secondary transient elevations of these immune biomarkers were observed to occur during IFN treatment and were followed by appearance of Th2 immune biomarker signatures that were associated with HBsAg seroconversion. Presentation Title: HBV Target Site for the RNA Interference Therapeutic Imdusiran is Highly Conserved in Chronic Hepatitis B Subjects: Key Findings: The imdusiran target site is highly conserved in baseline samples from cHBV subjects enrolled in imdusiran clinical studies assessed to date. In vitro testing in an HBV cell-based model confirmed retention of imdusiran activity against tested variants, suggesting that these single nucleotide polymorphisms have no apparent influence on HBsAg declines in subjects treated with imdusiran. Imdusiran has demonstrated clinical activity against HBV genotypes A-E.

08:27 EDT S&P Global appoints Eric Aboaf as CFO - S&P Global appointed Eric Aboaf as CFO, effective February 2025. He will report to Martina Cheung, S&P Global's incoming President and CEO, who assumes her role on November 1. Aboaf joins S&P Global from State Street where he has served as the company's CFO for nearly eight years, as well as Vice Chairman since 2022. Prior to his roles at State Street Corporation, Eric served as CFO for Citizens Financial Group. He also previously held senior financial roles during his twelve years with Citigroup, including as Treasurer. Earlier in his career, he was a partner at Bain & Company where he co-led the US financial services consulting practice and focused on growth strategy.

08:26 EDT Taboola introduces Abby generative AI assistant - Taboola announced the introduction of Abby, a Generative AI technology that advertisers can use to start and manage campaigns, even without being an expert in advertising. Nearly 91% of advertisers are already using or considering implementing Generative AI technology, according to industry data. Advertiser adoption for Generative AI has risen sharply recently as well, as a result of their desire to improve efficiency, drive more sales and return on investment-81% of advertisers believe it can increase sales for their organizations. Abby is an advanced AI assistant for advertisers that offers a conversational approach to building and launching every aspect of their campaigns-budgeting, targeting, creative, optimization and more. Abby is built on more than a decade of learnings from successful advertiser campaigns across Taboola and allows advertisers to launch effective campaigns in minutes, on a network of trusted premium publisher websites that reaches more than 600 million daily active users. In testing, advertiser campaigns launched with Abby were estimated to go live 75% faster than campaigns set up manually.

08:22 EDT Microchip adds 20 products to Wi-Fi portfolio - Microchip Technology has added 20 products to its Wi-Fi portfolio. Expanding one of the industry's most extensive wireless connectivity product lines, Microchip offers high-performance Wi-Fi microcontrollers, network and link controllers and plug-and-play modules designed to simplify development and speed time to market. The company's Wi-Fi solutions are designed to support various application needs and developer skill levels. The selection ranges from modules that are regulatory certified in several countries that require no Radio Frequency expertise and little programming to robust Systems-on-Chip with industrial-level features. Microchip's Wi-Fi portfolio includes: Wi-Fi MCUs: all-in-one solution designed to combine the functionality of an MCU with reliable wireless connectivity; Link Controllers: an SDIO interface enables the addition of Wi-Fi to Linux MPUs; Network Controllers: an SPI interface allows the addition of wireless connectivity to an MCU; Plug-and-Play Modules: simplify wireless-to-cloud connectivity by sending simple text commands from an MCU over a UART interface

08:18 EDT Rumble announces Sticker Mule as cloud client - Rumble announced that leading online custom merchandise seller Sticker Mule has become a cloud client. The retailer is moving its Artificial Intelligence processing to the Rumble Cloud and will be using Rumble's NVIDIA H100 inventory. This represents an expansion of an already successful relationship, as Sticker Mule has been a regular advertiser on Rumble for multiple years.

08:18 EDT Inari Medical partners with AVF, NBCA on DEFIANCE trial - In recognition of World Thrombosis Day, Inari Medical announced collaborative partnerships with the American Venous Forum and the National Blood Clot Alliance on the DEFIANCE trial. This prospective, multinational, randomized controlled trial will evaluate and compare clinical outcomes in patients with deep vein thrombosis treated with Inari's ClotTriever System versus anticoagulation alone. AVF is a non-profit society dedicated to improving the care of patients with venous and lymphatic disease, with members and leadership recognized internationally as thought leaders, expert investigators and top clinicians in the field. NBCA is the leading non-profit in the United States focused on building awareness and community among people who are affected by blood clots.

08:16 EDT Immuneering granted Orphan Drug Designation for IMM-1-104 - Immuneering announced that the U.S. Food and Drug Administration has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

08:14 EDT Akari Therapeutics announces effectiveness of Form S-4 related to merger - Akari Therapeutics announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. On March 5, 2024, Akari and Peak Bio announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Under the terms of the agreement, Peak Bio stockholders will receive a number of Akari ordinary shares for each share of Peak Bio stock they own, as determined on the basis of the exchange ratio described in the merger agreement. The exchange is expected to result in implied equity ownership in the combined company of approximately 50% for Akari shareholders and approximately 50% for Peak Bio stockholders on a fully diluted basis, subject to adjustment under certain circumstances, including based on each party's relative level of net cash at the closing of the proposed transaction. The transaction is expected to close in the fourth quarter of this year subject to the satisfaction of customary closing conditions, including approval by the shareholders of both companies.

08:13 EDT Indaptus initiates unrestricted enrollment on patients on Decoy20 weekly dosing - Indaptus Therapeutics provided an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee examined weekly administration data at the lower Decoy20 dose and cleared unrestricted enrollment of patients at this dose. The safety profile observed to date remains aligned with Decoy20's expected mechanism of action. The most clinically relevant treatment-related adverse events include Grade 2 Infusion Related Reaction and Grade 2 Hypotension, both of transient duration. "Unrestricted enrollment of patients at the lower Decoy20 dose will enable us to gather more safety and efficacy data, which is crucial for assessing the full potential of Decoy20. The data will guide how we initiate combination therapy next year, a critical phase in advancing Decoy20," said Dr. Roger Waltzman, Indaptus Chief Medical Officer. Jeffrey Meckler, CEO, added, "We continue to gather robust data on Decoy20, which remains consistent with our expectations from preclinical studies. We believe the continuation of this trial, and the eventual initiation of combination therapy studies presents an important opportunity to have a potentially significant impact on cancer immunotherapy. We look forward to sharing these results in the coming months."

08:12 EDT ICE: 517M contracts traded in Q3, including 276M energy futures/options - Intercontinental Exchange announced that its total futures and options markets reached record trading activity during Q3 2024 with 517M contracts traded during the quarter, including a record 276M energy futures and options. ...Record trading during Q3 2024 includes a record 173.3M oil futures and options, the highest volume traded since Q1 2020. ICE Brent traded at record quantities during the quarter with a record 93.4 million futures and options traded, hitting record average daily volume ADV of 1.5M during Q3 2024. In addition, Brent options hit record open interest of 3.77 million on October 11. Open interest across Brent futures and options is up 20% year-over-year y/y at 6 million contracts. Meanwhile, ICE Gasoil, which sits at the center of middle distillates trading as the global benchmark for refined oil products, saw record trading in options during Q3 with approximately 344,000 contracts traded. Gasoil futures and options hit record open interest of 1.3 M contracts on October 3, 2024, up over 60% y/y. ICE is home to over 800 oil futures and options contracts underpinned by the global benchmarks Brent and Gasoil. Other ICE oil benchmarks which hit record highs during the third quarter include ICE WTI futures and options with 23.7 million contracts traded, ICE Midland WTI HOU) futures which traded a record 1.6M and ICE Murban futures which traded a record 1.9 million contracts. ICE's energy markets include the broadest range of natural gas benchmarks to support globalization of the fuel. These include the global benchmark TTF, U.S. benchmark Henry Hub, Canadian benchmark AECO, U.K. benchmark NBP, and the benchmark for North-East Asia, ICE JKM LNG (Platts). Open interest across the complex is up 24% y/y, with TTF futures and options hitting record ADV of over 400,000 contracts during September 2024, up 30% y/y.

08:11 EDT BioVie receives notice of allowance for Japan patent application - BioVie announced that it has received a Notice of Allowance from the Japan Patent Office for patent application no. 2021-569344 entitled "Formulations of Terlipressin." This Notice of Allowance is expected to result in the issuance of a Japanese patent in 2 to 3 weeks once administrative processes are completed. The allowed claims cover a novel liquid formulation of terlipressin acetate that has stability at room temperature for two years and can be packaged in a pre-filled syringe. The patent supports BioVie's liquid formulation of terlipressin for development of a more patient-centric ambulatory treatment regimen for patients with ascites and hepatic failure in the US.

08:09 EDT Apollo Global closes second vintage large cap direct lending fund - Apollo has closed Apollo Origination Partnership Fund II with approximately $4.8 billion of investable assets. This brings total assets raised for the Apollo Large Cap Direct Lending business to approximately $13.3 billion in just over 12 months, inclusive of the Fund II close and other product formats providing access to Apollo's direct lending franchise. Apollo's total direct lending and performing credit AUM has doubled to $238 billion over the past four years. AOP II is designed to capitalize on growing demand for corporate and sponsor-backed large-cap lending. Under the strategy, Apollo aims to invest in senior corporate debt of issuers located predominantly in the United States and Western Europe that generate over $100 million of annual EBITDA.

08:08 EDT Vaxart to present norovirus data at IDWeek 2024 - Vaxart will present research demonstrating the potential of its norovirus oral pill vaccine candidate at IDWeek taking place October 16-19, 2024, at the Los Angeles Convention Center in Los Angeles. With no currently approved vaccines against norovirus, Vaxart remains committed to progressing what it believes to be the most advanced norovirus vaccine candidate in clinical development that is both formulated for oral administration and designed for delivery to the gastrointestinal system. Norovirus sickens approximately 21 million people in the United States each year, including the 15% of children under age 5 who contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work - approximately 2.2 days on average - to care for their children. Adults greater than or equal to65 years old are at high-risk for severe symptoms and clinical outcomes including longer disease duration and death. The annual disease burden from norovirus in the United States is estimated to be $10.6 billion

08:08 EDT American Rebel announces Connecticut launch party at Toad's Place - American Rebel Holdings announced American Rebel Beer's Connecticut launch party at the legendary Toad's Place in New Haven, Connecticut. This event features a live performance by Andy Ross, CEO of American Rebel, and is presented by Dichello Distributors."We are thrilled to partner with Dichello Distributors to bring America's patriotic beer, American Rebel Light Beer, to Connecticut," said Andy Ross. "Toad's Place is an iconic venue, and we are excited about an evening of rocking patriotic music and beer!"

08:07 EDT Chipotle to make minority investment in Lumachain - Chipotle Mexican Grill announced it is making a minority investment in Lumachain, an AI supply chain platform, and Brassica, a fast-casual restaurant concept, through its $100M Cultivate Next venture fund. Introduced in 2022, Cultivate Next makes early-stage investments into strategically aligned companies that further Chipotle's mission to Cultivate a Better World and help accelerate the company's longer term growth plans to operate 7,000 restaurants in North America.

08:06 EDT U.S. Army awards Javelin Joint Venture two production contracts worth $267M - The U.S. Army awarded the Javelin Joint Venture two production contracts totaling $267M for Lightweight Command Launch Units (LWCLU). These contracts support U.S. Army and Foreign Military Sales for Estonia, Latvia and Lithuania. Javelin is developed and produced by the JJV between Raytheon (RTX) in Tucson, Arizona and Lockheed Martin (LMT) in Orlando, Florida. To date, the JJV has produced more than 50,000 Javelin missiles and more than 12,000 reusable Command Launch Units. Production work under these contracts will take place in Tucson with estimated completion in 2026 and 2028.

08:04 EDT Monopar files provisional patent covering therapeutic radiopharmaceuticals - Monopar Therapeutics announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims cover a family of linkers, as well as Monopar's uPAR targeting agents linked with these along with therapeutic radioisotopes; Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar's array of therapeutic radiopharmaceuticals; Versatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies.

08:03 EDT Amgen announces 'positive' Phase 3 data for UPLIZNA - Amgen announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA for the treatment of adults with generalized myasthenia gravis, a rare autoimmune disorder. Results from this randomized, double-blind, placebo-controlled, parallel-group trial will be presented at the Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, taking place Oct. 15-18 in Savannah, Georgia. The trial met its primary endpoint, with a statistically significant change from baseline in Myasthenia Gravis Activities of Daily Living score for UPLIZNA (-4.2) compared with placebo (-2.2) at Week 26 for the combined study population. The study included patients who are acetylcholine receptor autoantibody-positive (AChR+) and those who are muscle-specific kinase autoantibody-positive (MuSK+), with participants receiving UPLIZNA or placebo on Day 1 and Day 15. UPLIZNA demonstrated continued improvement through Week 26. Notably, patients who entered the study taking corticosteroids were tapered down starting at Week 4 to prednisone 5 mg per day by Week 24. No new safety signals were identified.

08:03 EDT Pineapple Energy to implement 1-for-50 reverse stock split - Pineapple Energy announced that effective at 12:01 a.m. Central Time on October 17, 2024, the Company will implement a 1-for-50 reverse stock split of its outstanding common stock, which is within the range approved by stockholders at the annual meeting of the Company's shareholders held on July 19, 2024. The Company's common stock will continue to trade under the symbol "PEGY" and it is expected to open for trading on Nasdaq on October 17, 2024 on a post-split basis. The new CUSIP number for the common stock following the reverse stock split will be 72303P404. The reverse stock split is primarily intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid price required for continued listing on The Nasdaq Capital Market.

08:02 EDT Nabors Industries to acquire Parker Wellbore - Nabors Industries and Parker Wellbore announced a definitive agreement under which Nabors will acquire all of Parker's issued and outstanding common shares in exchange for 4.8M shares of Nabors common stock, subject to a share price collar. Parker provides drilling services across global energy markets. Through its Quail Tools subsidiary, Parker is the leading rental provider of high-performance downhole tubulars in the U.S. market. Internationally, Parker provides tubular rentals and repair services, with state-of-the-art facilities located in key geographies. Parker offers differentiated, casing and tubular running services in the U.S., the Middle East, Latin America, and Asia. Its portfolio also includes a fleet of 17 drilling rigs in the U.S. and international markets, as well as Operations & Maintenance services primarily in Canada and Alaska. The transaction is expected to result in immediate accretion to Nabors' free cash flow. It is further expected to be increasingly accretive to valuation metrics as expense and revenue synergies are progressively realized. The transaction has been approved by the Nabors and Parker Boards of Directors. Nabors will acquire Parker for 4.8 million shares and the assumption of net debt totaling approximately $100 million. The transaction is expected to close in early 2025, subject to customary closing conditions, as well as shareholder and regulatory approvals.

07:54 EDT Lucid Diagnostics granted patent underlying its EsoGuard Esophageal DNA Ttest - Lucid Diagnostics (LUCD), subsidiary of PAVmed (PAVM), has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method of using methylation of the cyclin-A1 gene to help detect esophageal precancer and cancer, a key component of its EsoGuard Esophageal DNA Test. Lucid Diagnostics markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer - the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Lucid holds the exclusive worldwide license to commercialize this technology. The successful transfer of the assay from the academic research laboratory and its subsequent commercialization was the result of collaboration between Lucid and Case Western Reserve University.

07:47 EDT Wolfspeed to receive $1B in Section 48D cash tax refunds from IRS

07:46 EDT Wolfspeed announces $750M in proposed funding from CHIPS Act - The U.S. Department of Commerce and Wolfspeed (WOLF) announced they have signed a non-binding preliminary memorandum of terms for up to $750M in proposed direct funding under the CHIPS and Science Act. In addition, a consortium of investment funds led by Apollo (APO), The Baupost Group, Fidelity Management & Research Company and Capital Group have agreed to provide Wolfspeed an additional $750M of new financing. Together these investments support Wolfspeed's long-term growth plans and bolster domestic production of silicon carbide to power clean energy systems underpinning electric vehicles, artificial intelligence data centers, battery storage and more. In addition, Wolfspeed expects to receive $1B of cash tax refunds from the advanced manufacturing tax credit under the CHIPS and Science Act, giving the company, in total, access to up to $2.5B of expected capital to support the expansion of silicon carbide manufacturing in the United States. Wolfspeed CEO, Gregg Lowe, said, "To reach this milestone under the U.S. CHIPS and Science Act is an incredible achievement in Wolfspeed's long-term growth strategy, and we believe today's announcement is a testament to the market-leading quality of Wolfspeed products and significance of Wolfspeed to broader U.S. economic and national security interests." These proposed funds, which are expected to be received upon milestone achievements in the coming years, would enable Wolfspeed to complete its multi-billion-dollar greenfield U.S. capacity expansion plan, which consists of the largest and most advanced 200mm silicon carbide footprint in the world. In addition to the proposed direct funding, Wolfspeed intends to benefit from the U.S. Treasury Department Investment Tax Credit of up to 25% of the qualified capital expenditures primarily related to its construction and installation of equipment at The John Palmour Manufacturing Center for Silicon Carbide in Siler City, NC and completion of the Mohawk Valley Fab M-Line West Expansion in Utica, NY.

07:40 EDT Alpha Metallurgical reports Q3 preliminary sales volumes and realizations - Alpha Metallurgical announced preliminary sales volumes and realizations for Q3. Q3 coal revenues for the Met segment were $669.8M, or $550.7M excluding freigh & handling. Q3 tons sold for the Met segment were 4.1M. Q3 coal sales realization for the Met segment is $132.76 per ton . Q3 net realized pricing for the Met segment was $132.76 per ton. "Our preliminary third quarter results reflect the market softness of the last few months, with revenues and shipment volumes both lower than in Q1 or Q2," said CEO Andy Eidson. "With a significant slowdown in spot activity during the quarter, we continued to fulfill our existing contracts, which resulted in 4.1 million tons shipped in Q3, and we believe we will end the year toward the higher end of our previously issued shipment guidance range. While the coal market indexes remain soft, we continue focusing on the controllable aspects of our business, including cost of coal sales, which we believe will end the year within the existing guidance range despite experiencing some additional adversity due to weather and mining conditions in the back half of the year. We look forward to providing additional information on Q3 when we announce our definitive results on November 1st, at which time we will also share our thoughts about 2025."

07:36 EDT Ocean Biomedical, Molecure sign licensing agreement for YKL-40 inhibitors - Molecure has signed an exclusive licensing agreement with Ocean Biomedical. The agreement concerns the development and commercialization of the selective YKL-40 inhibitor program, including the lead molecule OAT-3912, which Molecure has developed to early preclinical stage, as well as a second patent for a primary screening test enabling continuation of a continued discovery and development of novel YKL-40 modulators. Under the agreement, Ocean Biomedical gains the exclusive rights to further research, develop, manufacture and commercialize Molecure's OAT-3912 and other selective YKL-40 inhibitors worldwide and for all indications. As part of the collaboration, Molecure and Ocean Biomedical teams will continue development efforts through a joint steering committee overseeing research progress and commercialization processes. Under the agreement, Molecure will receive initial compensation of $600,000 in cash and stock. Molecure will receive further milestone payments upon achievement of preclinical & clinical development, regulatory & commercial milestones. The maximum bio-dollar value of the agreement amounts to approximately $32 million. Additionally, Molecure is also guaranteed additional revenues from the development and commercialization of other products containing selective YKL-40 inhibitors covered by the agreement, which Ocean Biomedical may choose to pursue. This deal is based on a discovery program carried out by Molecure, focused on the development of selective YKL-40 modulators, which may play a key role in various cancers and fibrotic diseases. This program led to the discovery of the lead compound OAT-3912, which strongly and selectively binds to YKL-40. In preclinical in vivo studies OAT-3912 demonstrated efficacy in cancer, as well as inflammatory and fibrotic diseases.

07:33 EDT Jazz Pharmaceuticals' Zepzelca combination meets endpoints in lung cancer trial - Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination with the PD-L1 inhibitor atezolizumab - Tecentriq- compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small cell lung cancer, or ES-SCLC, following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival and progression-free survival, compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial was consistent with the known safety profiles of Zepzelca and atezolizumab with no new safety signals observed in the combination arm. The company plans to submit an sNDA in the first half of 2025 to support this combination in the first-line maintenance setting for ES-SCLC.

07:32 EDT ZenaTech announces first US trial of ZenaDrone IQ nano drone - ZenaTech announced that its subsidiary, ZenaDrone, has begun the first US trial of the IQ Nano product solution for inventory management, beginning with a multinational auto part and components customer. The drone will be reading the bar codes and collecting inventory information as part of a paid trial. The IQ Nano indoor drone is designed for customers with warehouse, logistics and distribution operations to help them save costs and improve productivity by managing various tasks such as taking inventory, turning a weeklong activity into one day.

07:31 EDT Ocular announces accelerated timelines for SOL-1 registrational trial - Ocular Therapeutix announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration. The Company now expects the SOL-1 study to be fully enrolled with all patients randomized by the end of 2024. This is meaningfully ahead of prior guidance to complete enrollment by the end of the first quarter of 2025. With this update, topline data from the SOL-1 trial are now expected during the fourth quarter of 2025.

07:28 EDT Goldman Sachs reports Q3 FICC net revenue $2.96B, down 12% y/y - Net revenues in FICC were $2.96 billion, 12% lower than the third quarter of 2023, reflecting significantly lower net revenues in FICC intermediation, due to significantly lower net revenues in interest rate products and commodities, partially offset by significantly higher net revenues in currencies and credit products and higher net revenues in mortgages. Net revenues in Equities were $3.50 billion, 18% higher than the third quarter of 2023.

07:26 EDT Allied Properties announces commitment to set emissions reduction targets - Allied Properties Real Estate Investment Trusthas committed to set near- and long-term greenhouse gas emissions reduction targets, in line with the Science Based Targets initiative and a 1.5 degrees C decarbonization pathway. These targets will apply to both the rental and development portfolios. Allied will submit its targets for validation by the SBTi in the first half of 2025 and will disclose them once they have been validated.

07:19 EDT Ceco Environmental upsizes credit facility to $400M - CECO Environmental has announced a significant upsize in the form of an amendment and restatement of its credit facility, increasing it to a $400 million senior secured revolving credit facility. This expansion from the existing $246 million aggregate capacity underscores CECO's strategic commitment to strengthening its financial resources in pursuit of both organic and inorganic growth. The expanded credit facility comes with a five-year term and an option to increase the facility by $125 million. This move enables CECO with additional resources to efficiently fund potential opportunities and expand its footprint in global markets.

07:18 EDT Aclara Resources announces update rare earths separation project - Aclara Resources announced the completion of a conceptual engineering study for its rare earths separation project, currently being developed by its U.S.-based subsidiary, Aclara Technologies. The separation flowsheet concept, based on solvent extraction, was developed in collaboration with the Saskatchewan Research Council. This concept provided the foundation for Hatch to complete a Class 5-AACE CAPEX and OPEX estimate, while also incorporating robust environmental features such as significant waste reduction and zero liquid discharge. The initial results are highly encouraging, and positions Aclara to become the first vertically integrated heavy rare earths company outside of Asia. Separation of Key REE: Considers the separation of its mixed rare earth carbonates to be produced by the Company's Carina Project and the Penco Module to obtain high-purity didymium, dysprosium and terbium. Proven Technology: The flowsheet process employs solvent extraction technology with hydrochloric acid chemistry. High Purity: Achieves over 99.5% purity for all separated REE. Strong Metallurgical Recoveries: Expected metallurgical recoveries of 94% for NdPr, 92% for Dy and 91% for Tb. Environmental Features: Incorporates full water recirculation achieving no liquid discharge. Unoptimized CAPEX and OPEX: Initial CAPEX is estimated at US$ 354 million, which includes US$ 244 million for the solvent extraction plant andUS$110 million to significantly reduce waste and achieve zero liquid discharges. OPEX is estimated at US$ 12 per kg of rare earth oxides. Synergies with Circular Mineral Harvesting Process: The development of the separation project has uncovered significant synergies with Aclara's proprietary circular mineral harvesting process, leading to several new initiatives aimed at reducing CAPEX and OPEX at both mine and separation stages, minimizing waste management costs, and maximizing the quality of MREC output from the Carina Project and Penco Module. The Company has begun advancing the following activities as part of the next stage of development of its separation project: Trade-off Chemistry: Conducting a trade-off study comparing the base case of hydrochloric acid chemistry to a nitrate-based chemistry for the separation flowsheet process. Location Study: Conducting a detailed analysis within the U.S. to identify an optimal site for the contemplated industrial separation facility, with the goal of maximizing efficiency and minimizing cost and development timeline. Metallurgical Testing and Optimization: Executing bench scale and mini-pilot testing to optimize the contemplated separation flowsheet, CAPEX and OPEX. Based on these results, the Company will assess the implementation of an integrated piloting campaign and the development of a Class 3-AACE CAPEX and OPEX engineering study.

07:14 EDT BioXcel Therapeutics announces DOD grant to UNC to fund study of BXCL501 - BioXcel Therapeutics announced a collaboration with the University of North Carolina at Chapel Hill, UNC, on a grant awarded by the U.S. Department of Defense, DoD, to evaluate the efficacy and safety of BXCL501 as a potential treatment for acute stress disorder, ASD. The award provides $2.8 million to the UNC Institute for Trauma Recovery from September 15, 2024 through September 14, 2026 to evaluate the potential efficacy of BXCL501 to reduce ASD symptom severity and/or posttraumatic neuropsychiatric symptoms. The double-blind, placebo-controlled trial is expected to enroll 100 patients experiencing ASD resulting from motor vehicle collisions, beginning in the first half of 2025. BioXcel Therapeutics will supply BXCL501 for the trial.

07:13 EDT OTC Markets welcomes Medicenna Therapeutics to OTCQX - OTC Markets Group announced Medicenna Therapeutics has qualified to trade on the OTCQX Best Market. Medicenna Therapeutics Corp. upgraded to OTCQX from the OTCQB Venture Market.

07:12 EDT State Street CFO Eric Aboaf to depart - State Street announced that Eric Aboaf, vice chairman and CFO, has made the decision to accept a new opportunity outside of banking and is expected to leave State Street in February of 2025. State Street has commenced its succession plan with a formal internal and external search process and Aboaf will stay on and work closely with the State Street team into February to ensure an orderly transition.

07:10 EDT Gilat Satellite awarded $15M in orders from several major satellite operators - Gilat Satellite Networks announced that it has been awarded approximately $15 million in orders from several major satellite operators for its advanced satellite communications solutions for GEO, MEO and LEO constellations. The orders are expected to be delivered in several deliveries over the upcoming 18 months. "We are witnessing continuous demand for our innovative satellite communications solutions, as operators continue to expand their networks to meet the increasing needs of users worldwide," said Hagay Katz Chief Product and Marketing Officer. "Our portfolio ensures future-ready connectivity, serving diverse markets and applications with unparalleled reliability and reach."

07:10 EDT uniQure announces dosing of first patient in Phase I/II trial of AMT-162 - uniQure N.V. announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis, ALS, caused by mutations in superoxide dismutase 1, SOD1, a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with three dose-escalating cohorts assessing the safety, tolerability and exploratory signs of efficacy of AMT-162 in individuals with SOD1-ALS.

07:09 EDT Gray Media to debut new national anthem rendition across all stations - Gray Media announced the release of a new National Anthem rendition, which will begin airing across all Gray television stations starting Tuesday, October 15, 2024. This special performance honors the long-standing tradition of broadcasting the National Anthem daily, while shining a spotlight on the talent and dedication of younger generations. The video features a powerful performance by a youth orchestra, accompanied by a soloist who is one of Gray Media's own employees.

07:08 EDT Next Hydrogen completes extended durability test of GEN2 electrolysis cells - Next Hydrogen Solutions has completed an extended durability test of its GEN2 electrolysis cells used in the efficient production of green hydrogen. The GEN2 cells will now be deployed in Next Hydrogen electrolysers at customer sites for commercial operation. Next Hydrogen previously reported that it has achieved leading efficiency of its GEN2 cells in October of 2023. The GEN2 cell performance of lower than 1.9 V per cell at 1 amp/cm2 and at 70oC exceeds reported US Department of Energy technical targets status for energy efficiency, while maintaining a 2 times higher peak operating point. Further, a turn-down of 10% demonstrated best-in-class performance and an optimal solution for direct connection to renewables to produce green hydrogen. Equally important is the cell performance durability, and widely accepted testing protocols have been applied to confirm minimal degradation under intermittent operation as required for renewable energy supplied systems. Furthermore, 3,000 hours of cyclic testing have recently been successfully surpassed, providing the confidence to commercially deploy. The GEN2 cells will be applied to Next Hydrogen's modular product line in sizes of 0.75MW, 1.5MW and 2.25MW and offer the best commercially available performance features.

07:07 EDT Beamr Imaging enters collaboration with Bridge Digital - Beamr Imaging announced a collaboration with Bridge Digital Inc., a proven video technology integrator. Beamr's patented, GPU-based technology - available through scalable cloud services - significantly reduces video files sizes and live streams by up to 50%, while maintaining the same quality as the original. Combined with Bridge Digital Inc.'s extensive expertise, Beamr and Bridge Digital Inc. will offer a specialized service for companies and organizations with large-scale video repositories, including news, sports, entertainment and user-generated content for delivery and distribution. Beamr and Bridge Digital Inc. will enable companies that rely on video for their daily operations or manage vast video libraries to achieve "Forever Video" - future-proofing their content to ensure long-term compatibility through efficient, automatic, and scalable processes, all while significantly reducing costs.

07:05 EDT Cyngn expands dealer network to include Raymond West - Cyngn announced the expansion of its dealer network to include Raymond West. A leading distributor and integrator of intralogistics solutions, Raymond West will begin selling Cyngn's autonomous DriveMod Tugger. The autonomous tugger integrates Cyngn's AV technology with Motrec's MT-160.

07:03 EDT Lyra Therapeutics fully enrolls Phase 3 ENLIGHTEN 2 trial of LYR-210 - fLyra Therapeutic announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN 2 are expected in Q2 2025.

06:56 EDT Ryder authorizes new share repurchase program - Ryder has authorized a new discretionary share repurchase program. Under the new share repurchase program, Ryder management is authorized to repurchase up to 2.0 million shares of common stock, at its discretion, from October 9, 2024 through October 9, 2026. Ryder's previously authorized 2.0 million share discretionary repurchase program, authorized in October 2023, was completed in September 2024. In addition to the newly authorized discretionary share repurchase program, Ryder maintains an anti-dilutive share repurchase program authorized in October 2023. Under this program, Ryder management is authorized to repurchase up to 2.0 million shares of common stock through October 12, 2025 that have been issued to employees under the company's employee stock plans since August 31, 2023. This program is designed to mitigate the dilutive impact of shares issued under the company's employee stock plans. Through September 30, 2024, 753,000 shares have been repurchased under this program. As of September 30, 2024, the company had approximately 42.3 million shares of common stock outstanding.

06:46 EDT Pfizer appoints Tim Buckley to Board of Directors, effective immediately - Pfizer announced the election of Mortimer "Tim" Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Buckley was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Buckley, the Board will comprise 14 directors, 13 of whom are independent. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024.

06:37 EDT Nordic American Tankers announces long-term contract with energy company - Nordic American Tankers announced a five-year time charter contract with a major international energy company. The rate is in the mid-high 30's and the contract is expected to commence in November.

06:32 EDT Primo Water declares 82c per share special dividend - Primo Water announced that its board of directors declared a special dividend of 82c per share on its common shares, payable in cash on November 21 to shareowners of record at the close of business on November 5 in connection with the previously announced all-stock combination of Primo Water and BlueTriton Brands.

06:28 EDT Genmab reports Q3 net sales of Darzalex - Genmab announced that worldwide net trade sales of Darzalex, including sales of the subcutaneous product, as reported by Johnson & Johnson were $3.016M in Q3. Net trade sales were $1,684M in the U.S. and $1.332M in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

06:22 EDT UBS recovery, emergency plans to be revised due to Credit Suisse takeover - In its assessment of UBS's resolvability as at 31 December 2023, the Swiss Financial Market Supervisory Authority FINMA determined that the integration of Credit Suisse had created obstacles. FINMA is of the opinion that if the preferred restructuring strategy were to be applied, UBS could be resolved today by means of "single point of entry" recapitalization. UBS continues to fulfil the requirement for loss absorption capacity. However, due to the integration, it must harmonize the group structures, processes and IT platforms. The identified obstacles are currently being overcome by means of manual data aggregation until all processes function as automatically as possible again and the data is transferred to the strategic systems. At the same time, the current resolution strategy for UBS only provides for the continuation of business activities as part of a restructuring of the business model. Based on the experience of the Credit Suisse crisis, additional options for action are required to further strengthen crisis preparations and resolution planning for systemically important banks. Accordingly, FINMA also expects UBS to review its recovery and emergency plans. It has therefore suspended the annual assessment of these plans for 2024.

06:09 EDT Immuron reports Q3 sales of Travelan up 13% vs. Q2 - Immuron Limited announced continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Flavio Palumbo, Chief Commercial Officer, said, "As anticipated, we are achieving strong growth in North America with continued growth in Australia. We have secured core ranging in another nine pharmacy banner groups in Australia. We had our strongest monthly sales on amazon.com in the US. We now have distribution in ten pharmacy/grocery retailers in Canada." Global sales of Travelan for the September 2024 quarter were AUD$1.5M, up 13% on prior quarter; for Australia, Travelan sales increased 3% to AUD$1.007M during the September 2024 quarter vs. AUD$0.983M for the June 2024 quarter. In North America, Travelan sales increased 48% to AUD$0.456M in the September 2024 quarter vs. AUD$0.309M in the June 2024 quarter.

06:05 EDT Newmont, MKS PAMP partner to offer gold bar - Newmont and MKS PAMP partner to offer consumers a traceable gold bar exclusively made with Newmont-mined gold, refined and minted by MKS PAMP in Switzerland - powered by Provenance. The mine-to-market traceable PAMP 1oz Lady of Liberty gold bar is available at the largest U.S. wholesaler, making owning gold an accessible option for wealth building.

06:04 EDT Klotho Neurosciences names Peter Moriarty as COO - Klotho Neurosciences announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its COO.

05:48 EDT Argenx presents Vyvgart and ARDA data at AANEM meeting, MGFA sessions - Argenx announced the presentation of clinical and real-world data across its growing immunology pipeline at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine, or AANEM, annual meeting and Myasthenia Gravis Foundation of America, or MGFA, Scientific Sessions in Savannah, Georgia from October 15-18. The data presented at AANEM continue to demonstrate the significant impact of Vyvgart, the first-in-class neonatal Fc receptor blocker for people living with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Vyvgart is setting a new treatment standard in gMG and has shown rapid, deep and sustained responses, enabling a majority of patients to achieve minimal symptom expression with a consistent and favorable safety profile and more than 8,000 patient years of safety data. Based on real-world data, more than half of patients can reduce steroid use by greater than5mg/day following Vyvgart initiation. In CIDP, a majority of patients in the ADHERE trial responded to Vyvgart Hytrulo and experienced reduced risk of relapse versus placebo and improvements in motor function and muscle strength, regardless of prior CIDP treatment. Vyvgart demonstrates consistent improvement across gMG patient subtypes, including those on mestinon alone, indicating its efficacy in early line use. Real-world gMG data show that at one-year post Vyvgart initiation, 55% of patients reduced corticosteroid use by greater than or equal to 5 mg/day and 42% of patients had achieved steroid doses of less than or equal to5mg/day. Argenx is honoring its long-term commitment to the broader MG community with two Phase 3 studies ongoing in additional MG patient populations, including seronegative and ocular MG. Seronegative gMG patients evaluated in Vyvgart clinical studies experienced consistent and clinically meaningful MG-ADL improvements, including patients achieving MSE. Vyvgart Hytrulo showed sustained functional benefit in motor function and muscle strength, regardless of prior treatment, which was maintained through ADHERE and the open-label extension study. Vyvgart's consistent and favorable safety profile has been established across multiple autoimmune diseases with no increase in the incidence of adverse events with increased exposure. The unique safety profile of Vyvgart is further supported by no black box warnings, no labs or immunoglobulin monitoring, and no vaccination requirements. Argenx will also highlight two additional pipeline candidates, including Phase 2 ARDA data of empasiprubart for the treatment of multifocal motor neuropathy, and clinical trial designs of ARGX-119 (muscle-specific kinase for the treatment of congenital myasthenic syndromes and amyotrophic lateral sclerosis. Cohort 1 data from the Phase 2 ARDA study will be presented in a poster, showing treatment with empasiprubart for MMN reduced the risk of IVIg retreatment by 91% and demonstrated significant improvement in grip strength in both hands as compared to placebo. Data from a Patient Global Impression of Change scale show 94.4% of patients said they improved on empasiprubart from the start of the study, compared to 11.1% of placebo patients. As part of its commitment to the MMN community, argenx initiated the iMMersioN longitudinal study of approximately 150 patients to collect data on the impact of disease and burden of current treatment options on clinical outcomes and quality of life measures. A Phase 3 study of empasiprubart in MMN will start by the end of 2024.

05:32 EDT Crane NXT to acquire De La Rue authentication business for GBP 300M - Crane NXT announced it has signed a definitive agreement with De La Rue to acquire its authentication business for 300M British pounds in cash, subject to customary adjustments. De La Rue Authentication Solutions is a global leader in security and authentication technologies. The acquisition expands Crane NXT's portfolio to include security technologies for the identification documents and credentials market. De La Rue Authentication Solutions is a global provider of digital and physical security and authentication technologies to governments and brands, delivering more than 30-years of authentication solutions in nearly 80 countries. Their advanced security features include surface-relief micro-structures and holographic technologies. The acquisition is expected to close in the first half of 2025, subject to customary closing conditions. De La Rue Authentication generated approximately $130M in revenue in the fiscal year ended March 30, with an adjusted EBITDA margin of approximately 20%. Crane NXT expects the acquisition to be accretive to Adjusted EPS in the first full year and to achieve double digit ROIC by year five, driven by the growth outlook of De La Rue Authentication Solutions as well as transaction synergies.

05:25 EDT Lipella announces U.S. patent allowance for liposomal drug delivery platform - Lipella Pharmaceuticals announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office, or USPTO, for its proprietary liposomal drug delivery platform. The patent application, U.S. Patent No. 17/829,960, titled "Delivery of Agents Using Metastable Liposomes," covers key innovations in Lipella's platform technology for delivering therapeutic agents via liposome-based vehicles. The patent allows claims that cover Lipella's method for using metastable liposomes to deliver a variety of therapeutic agents, including the company's lead assets, LP-10 and LP-310. This technology enables precise, targeted delivery, improving the safety and efficacy of treatments across multiple therapeutic areas, including oncology, cancer survivorship, and immunotherapy. This newly allowed patent provides broad intellectual property protection for Lipella's drug delivery platform, which optimizes delivery to epithelial tissues such as those lining the mouth, bladder, colon, esophagus, vagina, and urethra. It extends market exclusivity and strengthens Lipella's competitive position, particularly for its two lead clinical assets currently in Phase 2 trials. With additional patents covering the company's formulations in the U.S., Australia, and Canada until 2035, Lipella is poised for further growth and development as it continues to advance its clinical pipeline.